Tumor-associated antigen (TAA) refers to antigen molecules present on tumor cells or normal cells, including embryonic proteins, glycoprotein antigens, squamous cell antigens, etc., which have been widely used for treating a number of tumors. In the past few years, many attempts have been made to developing various tumor drugs based on identified TAAs. The results have suggested that TAAs discovery for cancer therapy, novel systems for TAAs characterization, as well as the strategies to deliver the antigens, play important roles in developing therapeutic drugs for human cancers. Creative Biolabs can accelerate your TAAs discovery time and reduce the cost of drug development with state-of-the-art equipment and comprehensive TAA discovery platform.
Fig.1 Tumor-Associated Antigen (TAA) Discovery.
Our Services for TAA Discovery
Creative Biolabs has established a superior platform to offer a series of TAA discovery services for our worldwide customers. Currently, our services have been divided into three main parts:
Immune Effectors as Probes for TAA Identification
Pilot studies have shown that T lymphocyte-mediated immune effectors are critical for regulating tumor killing in humans. Two types of T cells, CD4+ T cells and CD8+ cytotoxic T lymphocytes (CTL) can be activated when following recognition of TAAs. As a consequence, these effectors have been considered as potential probes for identifying and defining TAAs. Basing on this platform, we have successfully identified various kinds of TAAs for our clients, including viral-related TAA, mutant forms of TAA, and TAA that are highly expressed in tumors.
Gene Expression Profiling for TAA Identification
Defined TAAs are potential targets for tumor therapy in humans. Gene expression profiling is a powerful tool for identifying a number of TAAs from specific tumor types. In Creative Biolabs, we have generated a wide collection of gene expression profiling assays to examine the possibility of overexpressed genes that can be further used to identify TAAs. For instance, a more recent study conducted by our labs has demonstrated that the gene expression levels can be examined for a panel of technologies, such as real-time PCR, next-generation sequencing, mRNA microarray scanning, and genome-wide approaches.
Tumor-Associated Antigen (TAA) Validation
Although there are many TAAs have been broadly used in drug development, most of TAAs are not tumor-specific in human. Therefore, the safety and efficacy of TAA still need to be validated. Creative Biolabs has developed a well-mature TAA validation platform for testing the expression and specificity of new TAA both in tumor and normal samples. Furthermore, a variety of immunological assays have also been established to evaluate immune responses against tumors.
Fig.2 Steps in the TAA discovery and validation process. (Radvanyi, 2004)
Highlights
Creative Biolabs provides comprehensive TAA discovery services to meet every customer’s needs. If you are interested in our services, please feel free to contact us for closer communication to learn how we can be involved in your project. Separate services or integrated end-to-end solutions are all welcomed.
Reference
For Research Use Only.
